Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

On Monday, Amgen Inc (AMGN) stock saw a decline, ending the day at $316.91 which represents a decrease of $-2.31 or -0.72% from the prior close of $319.22. The stock opened at $320.58 and touched a ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

Amgen reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and ...

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug ...

After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...

The Amgen STEM Learning Center — located at 260 Ramseyer Hall — opened Oct. 2, offering peer-led tutoring for first- and second-year students in introductory STEM courses. Susan Olesik, dean of ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...